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C1q/Tumor Necrosis Factor-Related Protein-3, a Newly
Identified Adipokine, Is a Novel Antiapoptotic,
Proangiogenic, and Cardioprotective Molecule in the
Ischemic Mouse Heart
Wei Yi, MD, PhD*; Yang Sun, MD*; Yuexing Yuan, PhD; Wayne Bond Lau, MD;
Qijun Zheng, MD, PhD; Xiaoliang Wang, MD, PhD; Yajing Wang, MD, PhD; Xiying Shang, PhD;
Erhe Gao, MD, PhD; Walter J. Koch, PhD; Xin-Liang Ma, MD, PhD
Background—Obesity and diabetes mellitus adversely affect postischemic heart remodeling via incompletely understood
mechanisms. C1q/tumor necrosis factor–related protein-3 (CTRP3) is a newly identified adipokine exerting beneficial
metabolic regulation, similar to adiponectin. The aim of the present study was to determine whether CTRP3 may
regulate postischemic cardiac remodeling and cardiac dysfunction, and, if so, to elucidate the underlying mechanisms.
Methods and Results—Male adult mice were subjected to myocardial infarction (MI) via left anterior descending coronary
artery occlusion. Both the effect of MI on endogenous CTRP3 expression/production and the effect of exogenous
CTRP3 (adenovirus or recombinant CTRP3) replenishment on MI injury were investigated. MI significantly inhibited
adipocyte CTRP3 expression and reduced the plasma CTRP3 level, reaching a nadir 3 days after MI. CTRP3
replenishment improved survival rate (P0.05), restored cardiac function, attenuated cardiomyocyte apoptosis,
increased revascularization, and dramatically reduced interstitial fibrosis (all P0.01). CTRP3 replenishment had no
significant effect on cardiac AMP-activated protein kinase phosphorylation but significantly increased Akt phosphor-
ylation and expression of hypoxia inducing factor-1 and vascular endothelial growth factor. Surprisingly, treatment of
human umbilical vascular endothelial cells with CTRP3 did not directly affect nitric oxide production or tube formation.
However, preconditioned medium from CTRP3-treated cardiomyocytes significantly enhanced human umbilical
vascular endothelial cell tube formation, an effect blocked by either pretreatment of cardiomyocytes with a PI3K
inhibitor or pretreatment of human umbilical vascular endothelial cells with a vascular endothelial growth factor
inhibitor. Finally, the protective effect of adipocyte-conditioned medium against hypoxia-induced cardiomyocyte injury
is significantly blunted when CTRP3 is knocked down.
Conclusion—CTRP3 is a novel antiapoptotic, proangiogenic, and cardioprotective adipokine, the expression of which is
significantly inhibited after MI. (Circulation. 2012;125:3159-3169.)
Key Words: adiponectin  myocardial infarction  revascularization  signal transduction
Cardiovascular disease remains a leading cause of mor-tality worldwide. Although improved reperfusion strat-
egies have led to declined death rates after acute myocardial
infarction (MI), both the incidence and prevalence of post-MI
heart failure have continually increased in recent years.1
Despite pharmacological advances (eg, -blockers, renin-an-
giotensin-aldosterone system inhibitors), mortality after MI
remains very high, with 5-year rates being 30% to 70%. Left
ventricular (LV) remodeling, which includes ventricular dil-
atation and increased interstitial fibrosis, is the critical pro-
cess underlying the progression to heart failure. A novel
approach preventing LV remodeling after MI is greatly
needed.
Editorial see p 3066
Clinical Perspective on p 3169
As a result of the increased incidence of diabetes mellitus
and its association with heart failure, there is now great
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interest in elucidating the underlying molecular mechanisms
linking these pathologies. Since their original discovery, the
important regulatory role of adipose-derived hormones and
cytokines (adipokines) in myocardial function has gained
recognition. Considerable evidence exists that the majority of
adipokines (including tumor necrosis factor [TNF]-, leptin,
plasminogen activator inhibitor type 1, transforming growth
factor-, and resistin) adversely regulate myocardial metab-
olism, cardiomyocyte hypertrophy, extracellular matrix struc-
ture and composition, and cell death.2 Despite having been
consistently shown to increase cardiomyocyte glucose up-
take, to stimulate fatty acid oxidation, and to protect against
acute myocardial ischemia/reperfusion injury,3 the effect of
adiponectin on chronic cardiac remodeling and heart failure
development remains controversial.4 Whether any adipokine
exerts beneficial regulatory effect on postischemic cardiac
remodeling, improving cardiac function, remains unknown.
Recently, a highly conserved family of adiponectin paral-
ogs, designated C1q/TNF-related proteins (CTRPs), was
discovered. Each of the 10 known members (CTRP1–
CTRP10) consists of 4 distinct domains, including an
N-terminal signal peptide, a short variable domain, a
collagen-like domain, and a C-terminal C1q-like globular
domain.5,6 Both CTRPs and adiponectin belong to the C1q/
TNF protein superfamily, which continues to grow as more
C1q domain proteins are discovered.7 Investigated for its
structural similarity to adiponectin, the CTRP family mem-
bers exhibit broadly diverse functions. CTRP3 (also known as
cartducin) is a growth plate secretory protein of primarily
cartilaginous origin but has also been reported in monocytic
and osteosarcoma cells.8 Initially identified during a search
for genes responsible for chondrocyte differentiation induc-
tion, CTRP3 also stimulates adiponectin and resistin release
and therefore serves as a regulator of adiponectin secretion
from adipocytes.9,10 Most important, CTRP3 is the first and
only CTRP for which the in vivo biological function (as a
metabolic regulator of glucose homeostasis) has been re-
cently established.11
Interestingly, CTRP3 has been reported to stimulate in
vitro endothelial cell proliferation and migration.12 However,
whether CTRP3 might promote in vivo revascularization in
the infarct border zones after MI is unknown. Moreover,
whether CTRP3, a key member of the newest adipokine
family, may function as a mediator or inhibitor of post-MI
remodeling has never been previously investigated. There-
fore, the aims of this study were (1) to determine the effect of
MI on CTRP3 expression/production, (2) to investigate the
effect of CTRP3 replenishment on postischemic cardiac
remodeling and dysfunction, (3) to determine whether
CTRP3 administration might promote revascularization after
MI, and (4) to elucidate the mechanisms responsible for the
cardiac biological actions of CTRP3.
Methods
All experiments were performed in adherence with the National
Institutes of Health guidelines on the use of laboratory animals and
were approved by the Thomas Jefferson University Committee on
Animal Care.
Experimental Protocols
Adult male C57/BL6 mice were anesthetized with 2% isoflurane,
and MI was induced via left anterior descending coronary artery
ligation as previously described.13 Sham-operated control mice
(sham) underwent the same surgical procedures except that the
suture placed under the left anterior descending was not tied. After
full recovery from cardiac surgery (4 hours after MI), animals were
randomized to one of the following groups: shamvehicle,
shamCTRP3, MIvehicle, MICTRP3 (0.25 g  g1  d1 intra-
peritoneal infusion via mini-osmotic pump, ALZET; DURECT
Corp, Cupertino, CA). After 2 weeks, mice were euthanized.
Immunohistological, biochemical, and Western blot assays were
performed as previously reported14 and described in detail in the
online-only Data Supplement.
Construct and Expression of Globular CTRP3
Globular domain of mouse CTRP3 gene was generated by polymer-
ase chain reaction and cloned into the prokaryotic protein expression
vector pET45b (Novagen, Merck, USA). The construct was verified
by DNA sequencing. Globular CTRP3 prokaryotic expression vector
was transferred into BL21 (DE3) bacterium protein expression host,
grown in LB medium, and shaken overnight at 37°C. Protein
expression inducer IPTG (isopropyl--D-thio-galactoside) was added
to the medium (final concentration, 1 mmol/L). The solution was
shaken for 4 to 5 hours and subjected to 5000-rpm centrifugation.
Proteins were purified in native condition by Ni-NTA resin per the
manufacturer’s instructions (Novagen, No. 70666–3, Merck, USA).
Endotoxin was removed by an endotoxin-removing column (Acti-
CleanEtoc resin, Sterogene, Carlsbad, CA). Proteins were desalted
and concentrated by centrifugation (Millipore-Centricon Plus-20).
Purified proteins were examined by Western blot analysis (Figure IA
and IB in the online-only Data Supplement), and the endotoxin
activity was determined by use of the LAL assay kit (BioWhittaker,
Walkersville, MD) according to the manufacturer’s recommendation
(27.63.9 EU/mg protein).
Adenoviral Vector Production and Transfection
Adenovirus expressing human full-length CTRP3 was constructed
by SinoGenoMax Co, Ltd (Beijing, China). Briefly, pShuttle-GFP-
CTRP3 was constructed by cloning the target gene CTRP3 into
pShuttle-GFP-CMV. After sequence confirmation, pShuttle-GFP-
CTRP3 was transferred into the recombinant adenovirus frame
vector of pADxsi. The pADxsi-GFP-CTRP3 adenovirus vector was
then amplified in 293 cells, and the viral titer was measured. Control
vectors (Ad.Null) not expressing CTRP3 but -galactosidase were
constructed and produced concomitantly. Then, 2108 plaque-
forming units of Ad.CTRP3 or Ad.Null was injected into the jugular
vein of mice 3 days before MI.
Statistical Analysis
Data were analyzed with GraphPad Prism-5 statistic software (La
Jolla, CA). All values in the text and figures are presented as the
meanSEM of n independent experiments. One-way ANOVA was
conducted across all investigated groups first. Post hoc tests were
then performed with Bonferroni correction, and all 2-group compar-
isons were made. Data presented in Figure 5A were determined by
2-way ANOVA followed by post hoc tests with Holm adjustment.
Survival data were analyzed by the Kaplan-Meier method followed
by the log rank test. Western blot densities were analyzed by the
Kruskal-Wallis test followed by the Dunn post hoc test. Values of
P0.05 were considered statistically significant.
All authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
MI Inhibits Adipocyte CTRP mRNA Expression
and Decreases Plasma CTRP3 Level
Clinical and experimental studies have demonstrated that plasma
adiponectin levels are significantly reduced after MI. However,
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the effect of MI on CTRP expression has not previously been
determined. Adipocyte CTRP3 mRNA expression significantly
decreased 1 day after MI and gradually recovered thereafter
(Figure IIA in the online-only Data Supplement). Consequently,
plasma CTRP3 levels (determined by Western blot densitometry
analysis) were significantly decreased after MI, reaching a nadir
3 days after MI and gradually recovering thereafter (Figure II in
the online-only Data Supplement, solid line). These results
demonstrate that CTRP3 expression/production is regulated
during post-MI cardiac remodeling.
Replenishment of CTRP3 Improves Survival and
Restores LV Cardiac Function After MI
Having demonstrated that adipocyte CTRP3 expression is inhib-
ited and that plasma CTRP3 levels are reduced in MI animals,
we attempted to determine whether post-MI CTRP3 reduction is
pathologically relevant and whether supplementation of exoge-
nous CTRP3 may protect the heart against post-MI remodeling.
As illustrated in Figure IIB in the online-only Data Supplement,
administration of recombinant CTRP3 via intraperitoneal os-
motic pump (dose, 0.25 g  g1  d1) caused an 1.5-fold
CTRP3 increase in sham-operated mice (open triangles con-
nected with dashed lines) and prevented MI-induced plasma
CTRP3 decline (open circles connected with dashed lines).
Administration of CTRP3 in sham-operated mice had no effect
on cardiac function assessed by echocardiography or ventricular
catheterization. However, CTRP3 administration significantly
improved the post-MI survival rate (Figure 1A), augmented the
LV ejection fraction (Figure 1B), increased dP/dtmax (Figure
1C), and decreased the LV end-diastolic pressure (Figure 1D).
These data demonstrate that pharmacological restoration of
plasma CTRP3 to physiological levels improved both LV
systolic and diastolic function in MI animals and increased the
survival rate.
CTRP3 Prevents LV Cardiac Remodeling
After MI
Because pathological remodeling plays a critical role in
postischemic cardiac dysfunction, we determined indexes of
remodeling by gross anatomy, echocardiography, and Mas-
son trichrome staining 14 days after MI. Compared with
MIvehicle, CTRP3 administration reduced heart size and
mass (Figure 2A and 2B) and preserved LV end-diastolic and
LV end-systolic dimension (Figure 2C and 2D). Most notice-
ably, CTRP3 treatment dramatically increased the ratio of
myocytes to fibrotic cells in the ischemic zone (Figure 3A),
significantly attenuated interstitial fibrosis (Figure 3B), re-
duced transforming growth factor-1 expression, and de-
creased cardiomyocyte size in remote nonischemic zone
(Figure 3C and 3D). Together, these results suggest that
endogenous CTRP3 may play a significant role in regulating
cardiac remodeling in post-MI hearts and that recombinant
CTRP3 may have therapeutic potential against MI injury.
CTRP3 Promotes Angiogenesis and Activates the
Akt–Hypoxia-Inducing Factor-1–Vascular
Endothelial Growth Factor Axis in Infarct
Border Zone
Angiogenesis is a critical step initiating cardiac repair after
MI. Having demonstrated that CTRP3 is a novel adipokine
potently inhibiting fibrosis and strongly augmenting cardio-
myocyte survival, we assessed the angiogenic effects of
CTRP3 as a potential underlying mechanism. As illustrated in
Figure 4A, CTRP3 treatment markedly increased the number
of CD31-positive capillary vessels and increased -smooth
muscle active–positive arterial density (Figure 4B) in the
border zone 14 days after MI, suggesting that CTRP3 induces
mature vessel formation after MI.
To further determine the molecular signaling mechanisms
responsible for increased angiogenesis after CTRP3 treatment,
Figure 1. C1q/tumor necrosis factor–re-
lated protein-3 (CTRP3) improves survival
and restores left ventricular cardiac func-
tion after myocardial infarction (MI). The
effects of CTRP3 treatment on survival
and left ventricular function were deter-
mined 14 days after operation. Wild-type
mice were subjected to MI or sham oper-
ation (Sham) and treated with CTRP3 or
saline as vehicle (Veh). A, Survival curve.
B, Echocardiographic analysis. C and D,
Hemodynamic analysis. LVEF indicates
left ventricular ejection fraction; LVEDP,
LV end-diastolic pressure. *P0.05,
**P0.01.
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several critical mediators and cytokines requisite for angiogen-
esis were assessed. CTRP3 had no significant effect on AMP-
activated protein kinase phosphorylation but significantly en-
hanced Akt phosphorylation and increased hypoxia-inducing
factor-1 (HIF1) and vascular endothelial growth factor
(VEGF) expression (Figure 4C–4F). These results suggest that
CTRP3 promotes angiogenesis after MI possibly through the
Akt-HIF1-VEGF axis.
Figure 2. C1q/tumor necrosis factor–re-
lated protein-3 (CTRP3) prevents left ven-
tricular (LV) cardiac remodeling after myo-
cardial infarction (MI). A, Gross
observation. B, Ratio of heart weight to
tibia length (HW/TL). C and D, LV end-di-
astolic and end-systolic dimensions
(LVEDD and LVESD) from echocardio-
graphic analysis. *P0.05, **P0.01.
Figure 3. C1q/tumor necrosis factor–re-
lated protein-3 (CTRP3) attenuates left
ventricular cardiac fibrosis after myocar-
dial infarction (MI). A, Cardiac Masson
trichrome staining. B, Interstitial fibrosis.
C, Western blot analysis for transforming
growth factor-1 (TGF-1) expression. D,
Cross-sectional area of cardiomyocytes in
the remote area. **P0.01.
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Adenoviral Supplementation of CTRP3
Significantly Attenuates LV Cardiac Remodeling
Recognizing that the globular domain of CTRP3 induced
angiogenesis and prevented LV cardiac remodeling, we
further determined the effect of adenoviral production of
full-length CTRP3 on adverse LV cardiac remodeling.
CTRP3-expressing adenovirus infection resulted in an 1.9-
fold increase in plasma CTRP3 before MI and maintained
plasma CTRP3 at significantly higher levels than seen in
Ad.Null-treated animals throughout the observation period
Figure 4. C1q/tumor necrosis factor–related protein-3 (CTRP3) promotes angiogenesis and activates the Akt-hypoxia-inducible factor-
1–vascular endothelial growth factor (HIF1-VEGF) axis in the infarct border zone. (A) Capillary density measured by immunohisto-
chemical staining for CD31 (brown) in the border region (myocardial infarction [MI] group) or left ventricular (LV) free wall (sham group).
B, Immunostaining for -smooth muscle actin (-SMA; green) and actinin (red) shown together with DAPI (blue) staining in the border
region (MI group) or LV free wall (sham group) 14 days after operation. Quantity of -SMA–positive vessels within the infarct border
zone is summarized by the bar graph. **P0.01. Western blot analysis for phosphorylated (p) AMP-activated protein kinase (AMPK)
(Thr172)/AMPK (C), pAkt(Ser473)/Akt (D), HIF1 (E), and VEGF-A (F). *P0.05, **P0.01.
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(Figure 5A). CTRP3 overproduction markedly improved
survival rate (Figure 5B) and restored left cardiac function
(Figure 5C). Moreover, CTRP3-expressing adenovirus signif-
icantly attenuated interstitial fibrosis in the remote area
(Figure 5D), increased CD31-positive capillary density (Fig-
ure 5E), and ameliorated terminal deoxynucleotidyl trans-
ferase dUTP nick-end labeling and -actinin double-positive
apoptotic cardiomyocyte death in the border zone (Figure
5F). Finally, transfection of neonatal cardiomyocytes with
adenoviral CTRP3 activated Akt and upregulated HIF1
expression in vitro (Figure III in the online-only Data
Supplement).
CTRP3 Does Not Significantly Promote
Angiogenesis in Cultured Human Umbilical
Vascular Endothelial Cells
Endothelial cells are essential in angiogenesis and postische-
mic cardiac repair. To directly investigate the effect of
CTRP3 on endothelial cells, we determined the effect of
CTRP3 on tube formation in cultured human umbilical
vascular endothelial cells (HUVECs) with VEGF as a posi-
tive control. Somewhat to our surprise, although in vivo
administration of CTRP3 significantly stimulated angiogen-
esis, direct HUVEC treatment with CTRP3 (both gCTRP3
and full-length CTRP3) failed to significantly promote tube
formation (Figure 6A) or stimulate nitric oxide (determined
as previously described14) production (Figure 6B). Moreover,
although in vivo CTRP3 treatment significantly increased
Akt phosphorylation and increased HIF1 and VEGF expres-
sion in the ischemic heart, in vitro treatment of HUVECs with
CTRP3 did not increase Akt phosphorylation or HIF1 or
VEGF expression (Figure 6C–6G). These results indicate that
the proangiogenic effect of CTRP3 observed in vivo cannot
be attributed to its direct effect on endothelial cells.
CTRP3 Promotes Angiogenesis via a
Cardiomyocyte-Initiated, Akt-Dependent Pathway
Recognizing that CTRP3 induced angiogenesis in vivo but
not in endothelial cells in vitro, we considered the hypothesis
that cardiomyocytes, in response to CTRP3 stimulation,
might secrete factors promoting angiogenesis in endothelial
cells (cardiomyocyte–endothelial cell communication). To
Figure 5. C1q/tumor necrosis factor–re-
lated protein-3 (CTRP3) adenovirus
improves survival, restores cardiac func-
tion, and attenuates left ventricular (LV)
cardiac remodeling. Ad.CTRP3 or Ad.Null
was injected into the jugular vein of mice
3 days before myocardial infarction (MI).
Effects of adenoviral CTRP3 supplement
on plasma CTRP3 level by Western analy-
sis (A), survival rate by survival curve
analysis (B), LV function by echocardio-
graphic analysis (C), and cardiac remod-
eling by interstitial fibrosis (D), angiogene-
sis (E), and cardiomyocyte apoptosis (F)
were determined 14 days after MI. LVEF
indicated LV ejection fraction; TUNEL,
terminal deoxynucleotidyl transferase
dUTP nick-end labeling. *P0.05,
**P0.01.
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test this hypothesis, adult mouse cardiomyocytes were iso-
lated as described in our previous study15 and treated with
CTRP3 in vitro for various periods (6, 12, and 24 hours). The
conditioned medium from CTRP3-treated cardiomyocytes
was then administered to cultured HUVECs for 6 hours. As
illustrated in Figure 7A, HUVEC treatment with conditioned
medium significantly enhanced HUVEC tube formation,
suggesting that CTRP3 invokes an angiogenic response by
inducing cardiomyocyte-secreted paracrine factors. Further-
more, CTRP3 upregulated levels of phosphorylated Akt,
HIF1, and VEGF in cultured cardiomyocytes in both a
time-dependent (Figure 7B and 7C) and dose-dependent
(Figure 7D) manner. These effects were not inhibited by
pretreatment with polymixin B (Figure IV in the online-only
Data Supplement). Additionally, blocking cardiomyocyte Akt
activation with a PI3-kinase inhibitor (LY294002) abolished
CTRP3-induced HIF1 and VEGF upregulation (Figure 7E)
and eliminated HUVEC tube formation induced by the
conditioned medium (Figure 7A, third bar). Finally, HUVEC
tube formation induced by the conditioned medium from
CTRP3-treated cardiomyocytes was significantly suppressed
by the VEGF receptor antagonist CBO-P11 (12 mol/L,
Calbiochem) administered directly to HUVECs (Figure 7A,
last bar).
The in vitro experimental results presented above demon-
strate that CTRP3 enhances HUVEC tube formation by
promoting cardiomyocyte/endothelial cell communication in-
volving Akt-HIF1-VEGF signaling. To determine whether
this signaling pathway is also responsible for CTRP3 cardio-
protection observed in vivo, LY294002 (to inhibit PI3-kinase
Akt axis) or CBO-P11 (to inhibit VEGF) was administered
together with CTRP3 via a mini-osmotic pump, and cardiac
function and capillary density were determined 14 days after
MI. As summarized in Figure 7F, CTRP3-induced capillary
formation was completely abolished when either Akt or
VEGF was inhibited. However, the cardiac protective effect
of CTRP3 (determined by LV ejection fraction) was com-
pletely blocked by LY294002 and partially blocked by
CBO-P11 (Figure 7G). These results suggest that although
the cardioprotective effect of CTRP3 is mediated largely by
Akt-HIF1-VEGF signaling–induced angiogenesis, other
mechanisms also contribute to the cardioprotection of CTRP3
against MI.
Endogenous CTRP3 Produced Under Physiological
Conditions Is Cardioprotective
In a final attempt to obtain more evidence that CTRP3 is an
endogenous cardioprotective adipokine, we performed an
additional in vitro experiment as recently reported.16 3T3-L1
fibroblasts (ATCC, Manassas, VA) were maintained per the
manufacturer’s protocol and transfected with CTRP3 siRNA
or scramble siRNA. Forty-eight hours after transfection, cells
Figure 6. C1q/tumor necrosis factor–related protein-3 (CTRP3) does not significantly promote angiogenesis in cultured human umbilical
vascular endothelial cells (HUVECs). A, Tube formation assay. HUVECs were treated with globular domain of CTRP3 (gCTRP3;
3 g/mL), full length CTRP3 (fCTRP3; 30 g/mL), vehicle, or vascular endothelial growth factor (VEGF; positive control) for 6 hours.
Representative experiment data are shown (n6 per condition). **P0.01 vs vehicle. B, Nitric oxide (NOx) formation assay. HUVECs
were treated with CTRP3 (3 g/mL) or vehicle for 12 hours. NOx formation was analyzed after 0.5, 1, 3, 6, and 12 hours as described
in our previous studies. C through G, Western blot analysis for pAkt(Ser473)/Akt, phosphorylated (p) AMP-activated protein kinase
(AMPK) (Thr172)/AMPK, hypoxia-inducible factor-1 (HIF1), and VEGF from cultured HUVECs treated with CTRP3 directly.
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were washed and cultured for an additional 6 hours. Condi-
tioned medium from 3T3-L1 cells was then collected. Adult
cardiomyocytes were isolated as described previously15; in-
cubated with regular control culture medium or conditioned
medium from control (no siRNA), scramble, or CTRP3
siRNA pretreated 3T3-L1 cells; and exposed to normoxic
(20% oxygen) or hypoxic (2% oxygen) conditions. Lactate
dehydrogenase concentration in culture medium and
caspase-3 activity in cardiomyocytes were determined 12
hours after normoxia/hypoxia incubation. Compared with
regular control medium, hypoxia-induced lactate dehydroge-
nase release (Figure 8A) and caspase-3 activation (Figure 8B)
were significantly attenuated in cardiomyocytes cultured with
conditioned medium from 3T3-L1 cells (second versus fourth
bar). Pretreatment of 3T3-L1 cells with scramble siRNA did
not alter the protective effect offered by adipocyte condi-
tioned medium (fourth versus fifth bar in Figure 8A and 8B).
However, the protective effect conferred by adipocyte-
conditioned medium was significantly blunted (last bars in
Figure 8A and 8B) when cardiomyocytes were cultured with
conditioned medium from CTRP3-knockdown 3T3-L1 cells
(722.2% reduced CTRP3 protein expression; Figure IC in
the online-only Data Supplement). These results indicate that
CTRP3 deficiency tilts the balance between cytoprotective
and cytotoxic molecules produced by 3T3-L1 cells, indicating
that CTRP3 is an endogenous cardioprotective adipokine.
Discussion
Our study presents several important observations. To the
best of our knowledge, we demonstrate for the first time that
Figure 7. C1q/tumor necrosis factor–related protein-3 (CTRP3) promotes angiogenesis via a cardiomyocyte-mediated, Akt-dependent
signaling mechanism in vitro. A, Tube formation assay. Isolated adult cardiomyocytes were pretreated with CTRP3 (3 g/mL) or saline
as vehicle for 12 hours. Human umbilical vascular endothelial cells (HUVECs) were treated with CTRP3-pretreated conditioned medium
(Pre-C3) or saline-pretreated medium (Preveh). Specific inhibitors of PI3-K (LY294002) and vascular endothelial growth factor (VEGF;
CBO-P11) were added to culture medium of cardiomyocytes or HUVECs, respectively. Western blot analysis showing time-dependent
activation of cardiac Akt (B) and cardiac expression of hypoxia-inducible factor-1 (HIF1) and VEGF in both cardiomyocytes (CMs)
and culture medium (C) after treatment with CTRP3 or vehicle. D, Western blot analysis showing a dose-dependent increase in VEGF in
both CMs and culture medium (n3). E, Western blot analysis showing that CTRP3-induced cardiomyocyte HIF1 and VEGF expres-
sion was blocked by LY294002. F, Capillary density measured by CD31 immunohistochemical staining in the border region. Results
show that CTRP3-induced capillary formation in vivo is abolished by coadministration of LY294002 or CBO-P11. G, Echocardiographic
analysis showing that cardiac functional improvement by CTRP3 is completely blocked by LY294002 (PI3-kinase/Akt signaling inhibi-
tion) and significantly inhibited by VEGF inhibition. LVEF indicates left ventricular ejection fraction. *P0.05, **P0.01.
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expression and production of CTRP3, a key member of a
newly identified adipokine family, are significantly reduced
after MI; (2) that replenishment of CTRP3 improves survival
and restores cardiac function after MI; (3) that CTRP3
attenuates postischemic pathological remodeling, as evi-
denced by reduced heart size, preserved LV chamber dimen-
sions, decreased remote-area interstitial fibrosis, increased
ischemic regional cardiomyocyte survival/regeneration, and
enhanced infarct border-zone revascularization and reduced
apoptosis; and (4) that CTRP3 exerts its angiogenic effect by
promoting cardiomyocyte–endothelial cell communication
involving Akt-HIF1-VEGF signaling.
The extent of tissue loss in the acute phase after MI is a
major determinant of the resultant cardiac dysfunction de-
gree. However, chronic processes such as extracellular matrix
turnover, fibrosis, and inflammation stimulate adverse re-
modeling and are crucial determinants in the transition from
compensatory cardiac hypertrophy to decompensatory heart
failure.17 Many cytokines have been reported either to medi-
ate post-MI adverse remodeling or to prevent cardiac remod-
eling and dysfunction. It is thus widely accepted that the
degree of post-MI cardiac remodeling is critically dependent
on the balance between detrimental and protective cyto-
kines.18 As a result of the increased incidence of diabetes
mellitus and its association with heart failure, the role of
adipocyte-derived cytokines (adipokines) in the development
of postischemic remodeling has attracted great attention.2 The
effects of leptin and adiponectin, among many adipokines
examined, on cardiac remodeling have been investigated
extensively in recent years. The majority of published studies
demonstrate the opposing effects of these adipokines on
postischemic remodeling, and the balance between detrimen-
tal leptin and protective adiponectin is critically influential on
post-MI heart failure development.19,20 In patients with type 2
diabetes mellitus, the balance is disturbed, with markedly
increased plasma leptin levels and significantly reduced
plasma adiponectin levels favoring adverse cardiac remodel-
ing.2 Therefore, identifying cardioprotective adipokines and
augmenting their production are scientifically and clinically
imperative. In the present study, we have provided the first
direct evidence that CTRP3 is an adipokine possessing strong
antiremodeling and cardioprotective properties, suggesting
that CTRP3 might be a novel therapeutic target attenuating
postischemic cardiac remodeling, thereby improving cardiac
function.
Angiogenesis represents an excellent therapeutic modality
for ischemic heart disease treatment. Many preclinical studies
have been performed with gene-, cell-, and protein-based
therapies.17 Gene therapy, once regarded as a potential
advanced treatment of choice for cardiovascular disease,
remains impractical for regular clinical application because of
many serious, unsolved problems. Cell-based proangiogenic
therapies linger in early research stages, hindered by numer-
ous unresolved questions regarding best usable cell types and
dosages. The failure of gene- or cell-based therapeutics to
deliver, as of yet, a suitable treatment choice for diseases
stemming from poor blood flow has led to a resurgence of
interest in returning to protein-based therapies stimulating
angiogenesis.
Among many different growth factors implicated in angio-
genesis, VEGF and fibroblast growth factor are the 2 most
intensively investigated growth factors. Numerous animal
model experimental studies have demonstrated that VEGF or
fibroblast growth factor treatment stimulates angiogenesis
with great efficacy, increasing capillary quantity and allevi-
ating postischemic remodeling.21 Reproducible and credible
successes in these early animal studies garnered enthusiastic
expectations that new therapeutic approaches could be rap-
idly translated for clinical benefit in millions of MI patients.
Unfortunately, despite the optimistic early data of many
pioneering clinical trials, recent larger and better-designed
clinical trials have reported one disappointment after an-
other.22–24 These failures suggest incorrectly selected molec-
Figure 8. Endogenous C1q/tumor necrosis factor–related
protein-3 (CTRP3) produced under physiological conditions is
cardioprotective. Lactate dehydrogenase (LDH) release (A) and
caspase-3 activity (B) from adult cardiomyocytes (cultured with
regular culture medium, adipocyte-conditioned medium with or
without CTRP3 knockdown) exposed to normoxia or hypoxia
(2% O2 for 12 hours). Con-M indicates conditioned medium;
EC, endothelial cell. *P0.05, **P0.01. C, Proposed mecha-
nism responsible for the cardioprotective effects of CTRP3 after
myocardial infarction (MI).
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ular targets inducing neovascularization, improper therapeu-
tic agent formulation or administration, or ignorance of the
overall cellular microenvironmental context, affecting thera-
peutic utility and efficacy. Presentation of therapeutic pro-
teins in a manner mimicking natural signaling events, ac-
counting for concentration, spatial and temporal profiles, and
their simultaneous or sequential presentation with other
appropriate factors, may be requisite for salutary effects.
Our present study demonstrates that CTRP3 effectively
promotes postischemic angiogenesis and attenuates adverse
remodeling. More interesting, we have demonstrated that
CTRP3 stimulates angiogenesis by promoting cardiomyo-
cyte–endothelial cell communication, a process closely mim-
icking natural cardiac signaling events. Considerable evi-
dence supports that communication between endothelial cells
and cardiomyocytes regulates not only early cardiac devel-
opment but also adult cardiomyocyte function, including the
contractile state.25 Cardiomyocytes depend on endothelial
cells, not only for oxygenated blood supply but also for
locally protective signals promoting cardiomyocyte organiza-
tion and survival. Although endothelial cells direct cardio-
myocytes, cardiomyocytes reciprocally secrete factors affect-
ing endothelial cell function. Specifically, cardiomyocyte-
specific deletion of VEGF-A results in vasculogenic/
angiogenic defects and a thinned ventricular wall.26
Additionally, erythropoietin, a cardioprotective cytokine, has
recently been demonstrated to promote angiogenesis by
increasing cardiomyocyte VEGF expression.27 It is thus
highly likely that interventions stimulating the ongoing mo-
lecular conversation between endothelial cells and cardio-
myocytes may more closely mimic natural cardiac develop-
ment events and thus exert superior cardioprotection
compared with direct growth factor administration. Currently,
whether CTRP3 may stimulate other mediators required for
different angiogenesis stages remains unknown. However,
the fact that CTRP3 is known to directly promote endothelial
cell proliferation and migration, but not enhance tube forma-
tion (a process requiring complexity beyond proliferation and
migration), suggests that proangiogenic factors other than
VEGF might also be released by cardiomyocytes after
CTRP3 treatment. This intriguing possibility will be investi-
gated in our future studies. Moreover, although our in vitro
experiments demonstrated that conditioned medium from
CTRP3-treated cardiomyocytes promotes angiogenesis in
cultured endothelial cells and that CTRP3 significantly pro-
moted angiogenesis in MI heart, administration of CTRP3 in
the sham-operated control heart only slightly increased cap-
illary density. These results suggest that under normal phys-
iological conditions (in vivo normal heart), angiogenesis is
tightly controlled by a balance between proangiogenesis and
antiangiogenesis factors and that the proangiogenic effect of
CTRP3 cannot be observed under this condition. The impor-
tant underlying mechanisms responsible for the differences
between in vitro and in vivo experimental results and between
normal and MI heart will be directly investigated in our future
experiments.
It is worth noting that the CTRP3-treated group manifested
not only significantly increased angiogenesis and dramati-
cally reduced fibrosis but also marked preservation of intact
myocytes in the infarct area at risk. The precise mechanisms
responsible for this protection are likely complex and cannot
be answered in a single experiment. Multiple possibilities
exist. First, the potent antiapoptotic effect of CTRP3 ob-
served in the border zone may block or attenuate infarct
expansion. Second, the significant angiogenic effect of
CTRP3 observed in the border zone may facilitate blood flow
restoration, thus salvaging dying cardiomyocytes in infarcted
regions, and/or promote endothelial cell transdifferentiation
into cardiomyocytes.28 Finally, CTRP3 may promote homing
of stem cells from bone marrow and/or stimulate differenti-
ation of resident cardiac stem cells. Such intriguing possibil-
ities all warrant direct investigation.
Although CTRP3 is a paralog of adiponectin, our present
study demonstrates distinctly different cardioprotective sig-
naling between CTRP3 and adiponectin. It is well accepted
that adiponectin promotes angiogenesis via AMP-activated
protein kinase signaling activation and augments nitric oxide
production.29 However, CTRP3 had no significant effect on
AMP-activated protein kinase or endothelial nitric oxide
synthase phosphorylation and failed to stimulate nitric oxide
production. In contrast, CTRP3 induced significant Akt
phosphorylation both in vivo and in cultured cardiomyocytes.
More important, inhibition of Akt phosphorylation abolished
CTRP3-induced HIF1 and VEGF expression and blocked
the angiogenic effect of CTRP3. These results support an
Akt-dependent mechanism for angiogenic effects of CTRP3.
Conclusions
We have demonstrated that CTRP3, a key member of a newly
identified adipokine family, directly prevented apoptotic
death of cardiomyocytes, increased cardiomyocyte survival/
regeneration, attenuated postinfarct fibrosis, and enhanced
cardiomyocyte expression of angiogenic cytokines inductive
of robust angiogenesis, thus attenuating post-MI remodeling
and augmenting post-MI contractile function (Figure 8E).
Preventing post-MI CTRP3 inhibition or CTRP3 supplemen-
tation may be a promising therapeutic avenue for creating
stable and functional vessels in postinfarcted myocardium,
restoring cardiac function, and mitigating the heart failure
phenotype.
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CLINICAL PERSPECTIVE
Cardiovascular disease remains a leading cause of mortality worldwide. Although improved reperfusion strategies have led
to declined death rates after acute myocardial infarction, both the incidence and prevalence of post–myocardial infarction
heart failure have continually increased in recent years. As a result of the increased incidence of diabetes mellitus and its
association with heart failure, there is now great interest in elucidating the underlying molecular mechanisms linking these
pathologies. Considerable evidence exists that the majority of adipokines (including tumor necrosis factor [TNF]-, leptin,
plasminogen activator inhibitor type 1, transforming growth factor-, and resistin) adversely regulate myocardial
metabolism, cardiomyocyte hypertrophy, extracellular matrix structure and composition, and cell death. The present study
demonstrated that C1q/TNF-related protein-3 (CTRP3), a key member of a newly identified adipokine family, exerts
cardiac actions opposing the majority of other adipokines and is a novel and potent cardioprotective molecule. Expression
and production of CTRP3 are significantly reduced after myocardial infarction, and replenishment of CTRP3 protects the
heart by attenuating postischemic pathologic remodeling and promoting cardiomyocyte–endothelial cell communication.
These results suggest that the balance between cardioprotective and cardio-harmful cytokines tilts during pathological
conditions such as heart failure. Interventions restoring the balance may represent a novel therapeutic strategy in the
treatment of cardiovascular diseases, particularly in those patients with diabetes mellitus.
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Methods: 
Determination of cardiac function: Cardiac function was determined by 
echocardiography as well as left ventricular catheterization. Determination of cardiac 
function occurred 2 weeks after mini-osmotic pump implantation, prior to 
thoracotomy, as described previously. 
Histological analysis: Hearts were fixed with 4% paraformaldehyde, embedded in 
paraffin, and either coronally (for myocyte/fibrosis ratio in left ventricular free wall) 
or transversely(for all other assays) sectioned (6 μm thick). Five sections from each 
heart were mounted upon glass slides, and stained with Masson trichrome (for fibrosis 
determination), wheat germ agglutinin (for myocyte size), antibody against CD31 (for 
capillary density), or antibody against -smooth muscle actin (-SMA, for arteriolar 
density). Slides were examined with an Olympus IX51 microscope, and 5 images 
from each slide were captured by a Q-Imaging camera controlled by IP Lab 4.0 
software. Myocyte/fibrosis ratio (left ventricular free wall), cardiac collagen deposit 
(remote non-infract area), and capillary/arteriolar density (infarct border zone) were 
determined as previously reported
1, 2
. Results from all slides obtained in the same 
heart were averaged, and counted as n=1.     
Western blot analysis: Proteins of interest were separated on SDS-PAGE gels, 
transferred to PVDF membranes, and incubated with appropriate primary antibodies 
followed by horseradish peroxidase-conjugated secondary antibody. Blots were 
developed via SupersignalChemiluminescence detection kit (Pierce, Rockford, Ill). 
Bands were visualized with a Kodak Image Station 4000 (Rochester, NY). 
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Tube formation assay: 100 μl of Matrigel (growth factor reduced, BD Biosciences) 
was added to each well of a 48-well plate, and polymerized at 37°C for 1 hour. 
HUVECs (1 × 10
4
) were seeded onto Matrigel, in endothelial cell basal medium-2 
with EGM-2 Bullet Kit. After 1 hour culture, gCTRP3 (3 g/ml) or full length CTRP3 
(30 g/ml) was added. For conditioned medium experiments, endothelial cell basal 
medium-2 was replaced with cardiomyocyte-conditioned medium after 1 hour culture. 
After an additional 6 hour-culture, tube length was quantified via IP Lab 4.0 image 
analysis software.  
Assessment of cardiomyocyte apoptosis: Cardiomyocyte apoptosis was determined 
via TUNEL staining and caspase-3 activity, as reported previously
3
. 
Measurements of endotoxin activity: The endotoxin activities of globular CTRP3 
preparations were determined using the LAL assay kit (catalog No.50–648U, 










































Figure S1. Western blots of recombinant globular domain of CTRP3 and CTRP3 
SiRNA efficiency: Western blots of recombinant globular domain of CTRP3 with an 
antibody against His (A) or against CTRP3 (B); (C) Western blot of knock-down 
efficiency of mouse CTRP3 specific SiRNA. **P<0.01. 
 at Thomas Jefferson Universi on August 17, 2013http://circ.ahajournals.org/Downloaded from 




















































































** ** ** 
* 
Figure S2. MI significantly inhibited adipocyte CTRP3 mRNA expression (A) and  
decreased serum CTRP3 levels (B, closed green circles connected with solid line).  
Supplementation of recombinant CTRP3 with an osmotic pump increased plasma  
CTRP3 levels in sham-operated mice (open blue triangles connected with dashed line) 
and prevented MI-induced serum CTRP3 reduction (open green circles connected 
with dash line).  N=6/each time point; *P<0.05, **P<0.01 vs. MI+ Vehicle.  























































CON Ad.Null Ad.CTRP3 CON Ad.Null Ad.CTRP3 
A B 
Figure S3. Adenoviral CTRP3 transfection of neonatal cardiomyocytes activated Akt (A) and upregulated 
HIF1α expression (B). Neonatal cardiomyocytes were transfected with Adenoviral CTRP3, and phospho-
Akt (473)/Akt and HIF-1/β-tubulin were determined 24 hours after transfection.  Ad.Null had no 
significant effect upon Akt phosphorylation or HIF-1 production, but Ad.CTRP3 significantly enhanced 
Akt phosphorylation, and increased HIF1-α expression. *P<0.05, **P<0.01. 






























































Figure S4. Cardiomyocyte Akt activation (A) and VEGF expression (B) in response to 
globular CTRP3 treatment were not blocked by polymixin B (PMB, 30μg/mL).  




















Figure S5. Treatment with CTRP slightly 
reduced infarct size. However, the difference 
is not statistically significant. 
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